Sanofi's Hexacima, a 6-in-1 Combination Vaccine, Receives Final Marketing Authorization from the European Medicines Agency
Innovative 6-in-1 Vaccine Disrupts the Monopolistic Market
Sanofi's Hexacima (DTaP-IPV-HB-Hib), a 6-in-1 combination vaccine for infants, has received final marketing authorization from the European Medicines Agency (EMA). This approval marks a turning point in the European 6-in-1 vaccine market, which was previously dominated by GlaxoSmithKline's (GSK) Infanrix hexa. Hexacima targets six antigens – Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Hepatitis B surface antigen (HBsAg), inactivated Poliovirus (IPV), and Haemophilus influenzae type b polysaccharide (Hib Polysaccharide) – providing robust protection. Following the positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) on February 21, 2013, Sanofi is now poised to compete for market share.
The 'Fully Liquid' Formulation Offers a Differentiated Competitive Advantage
The key advantage of Hexacima is its fully liquid, ready-to-use formulation, which eliminates the need for a cumbersome dilution process. The existing competitor, Infanrix hexa, required healthcare professionals to mix a powdered lyophilized component with a liquid component. Hexacima eliminates this step, reducing the risk of administration errors and significantly shortening the preparation time for healthcare professionals. This is considered a technological innovation that not only improves the convenience of vaccine administration but also significantly enhances the safety of administration in clinical settings.
Enhancing Public Health and National Immunization Programs
For government agencies that operate National Immunization Programs (NIPs), the approval of Hexacima is welcome news. By providing protection against six diseases with a single injection, it reduces the pain of injections for infants and the number of hospital visits for parents. This improves immunization compliance and contributes to strengthening the overall national immune barrier. Furthermore, it reduces the storage space required for vaccines and the amount of waste generated, which has a positive impact on the efficient allocation of public health budgets.
Securing Strong Growth Momentum for Sanofi's Vaccine Business
This European approval is expected to be a significant driver of long-term revenue growth for Sanofi's polio/pertussis/Hib (PPH) vaccine business. Sanofi's PPH franchise is a key cash cow business that generates hundreds of millions of euros in revenue each quarter. By launching a new product with superior technology in a market previously dominated by a single player, Sanofi has solidified its position in the high-value combination vaccine market. This also provides a solid foundation for accelerating expansion into global markets beyond Europe.
Sanofi's (SNY) Hexacima, a 6-in-1 vaccine, receiving marketing authorization in Europe represents a pivotal moment, reshaping the multi-billion dollar European pediatric 6-in-1 vaccine market, previously dominated by GlaxoSmithKline's (GSK) Infanrix hexa, into a duopoly. Its unique fully liquid formulation, eliminating the need for dilution, offers superior convenience, leading to reduced administration errors and faster preparation times in clinical settings, which will likely maximize its success in securing contracts in European National Immunization Programs (NIPs) in the short term. In the medium to long term, its demonstrated high immunogenicity and safety profile in multinational Phase 3 trials are expected to contribute to the growth of Sanofi's core polio/pertussis/Hib (PPH) vaccine business, which generated €664 million in quarterly revenue in Q1 2026. Furthermore, this final approval validates the complex antigen delivery technology used in the manufacturing of multivalent vaccines, paving the way for faster development and global regulatory approvals of future pediatric vaccines.
Source: EMA (ema)